Christopher Price

Sep 25, 2024 | emj.bmj.com | Christopher Price |Gary Ford |Phil White |Martin James

Accessing mechanical thrombectomy treatment for stroke in England, Wales and Northern Ireland: the importance of the emergency pathway Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Aug 29, 2024 | emj.bmj.com | Christopher Price |Gary Ford |Phil White |Martin James

Severe disability due to large vessel occlusion (LVO) stroke can be avoided by emergency mechanical thrombectomy (MT)1 but provision varies nationally and internationally according to the availability of specialist facilities. Across England, Wales and Northern Ireland, only 26 hospitals can offer treatment,2 and the majority of stroke patients are instead admitted to local non-MT hospitals.

Dec 13, 2023 | biorxiv.org | Christopher Price |Dylan Stavish |Owen Laing |Theodore Wing

AbstractHuman pluripotent stem cell (hPSC)-derived cardiomyocytes have emerged as powerful tools for disease modelling and cell therapy. The production of cardiomyocytes from hPSCs typically requires expanding large numbers of hPSCs and maintaining them in culture for extended periods of time. This in turn predisposes hPSCs to the acquisition of non-random genetic changes, including recurrent gains of chromosome 1q.

Sep 21, 2023 | biorxiv.org | Dylan Stavish |Christopher Price |Gabriele Gelezauskaite |Kimberly A. Leonhard

AbstractSince the first derivation of human pluripotent stem cells (hPSCs), the number of culture conditions has steadily increased, making hPSC culture more facile. Nonetheless, there remains the persistent issue of culture-acquired genetic changes, hampering the reproducibility of hPSC research and jeopardising their clinical use.